Advertisement
Advertisement
JAZZ
Jazz Pharmaceuticals, Inc.
183.24
USDSponsored
-5.45
-2.89%
Mar 05, 15:06 UTC -5
Open
JAZZ Earnings Reports
Positive Surprise Ratio
JAZZ beat 22 of 41 last estimates.
54%
Next Report
Date of Next Report
May 04, 2026
Estimate for Q1 26 (Revenue/ EPS)
$1.01B
/$4.95
Implied change from Q4 25 (Revenue/ EPS)
-15.48%
/-25.45%
Implied change from Q1 25 (Revenue/ EPS)
+12.77%
/+194.64%
Jazz Pharmaceuticals, Inc. earnings per share and revenue
On Feb 24, 2026, JAZZ reported earnings of 6.64 USD per share (EPS) for Q4 25, missing the estimate of 6.64 USD, resulting in a -0.11% surprise. Revenue reached 1.20 billion, compared to an expected 1.19 billion, with a 0.79% difference. The market reacted with a +13.23% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 9 analysts forecast an EPS of 4.95 USD, with revenue projected to reach 1.01 billion USD, implying an decrease of -25.45% EPS, and decrease of -15.48% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Liquidia Corporation Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.18
Actual
$0.15
Surprise
-18.48%
EyePoint, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.76
Actual
-$0.81
Surprise
-6.20%
Kura Oncology, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.62
Actual
-$0.92
Surprise
-47.84%
CorMedix Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.83
Actual
$0.61
Surprise
-26.73%
Keros Therapeutics, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.64
Actual
-$0.86
Surprise
-34.10%
REGENXBIO Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.97
Actual
-$1.30
Surprise
-33.31%
Lexicon Pharmaceuticals, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.07
Actual
-$0.04
Surprise
+43.18%
Ocugen, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.06
Surprise
-1.35%
Niagen Bioscience, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
$0.02
Actual
$0.03
Surprise
+33.93%
Aligos Therapeutics, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$1.88
Actual
-$1.91
Surprise
-1.11%
FAQ
What were Jazz Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Jazz Pharmaceuticals, Inc. reported EPS of $6.64, missing estimates by -0.11%, and revenue of $1.20B, 0.79% above expectations.
How did the market react to Jazz Pharmaceuticals, Inc.'s Q4 2025 earnings?
The stock price moved up 13.23%, changed from $173.83 before the earnings release to $196.83 the day after.
When is Jazz Pharmaceuticals, Inc. expected to report next?
The next earning report is scheduled for May 04, 2026.
What are the forecasts for Jazz Pharmaceuticals, Inc.'s next earnings report?
Based on 9
analysts, Jazz Pharmaceuticals, Inc. is expected to report EPS of $4.95 and revenue of $1.01B for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement